Sentences with phrase «cell infusion»

Johns Hopkins researchers then study stem cell infusion as therapy for cancer treatment toxicity, diabetes, cystic fibrosis, and other diseases.

Also, the researchers are confident that the stem cell infusion holds promise for primary open - angle glaucoma (where the pressure in the eye rises slowly), which is the most common form of the disease.

Seven of the eight patients treated had active disease at the time of T - cell infusion.

It is ironic that in patients with very high underlying risks already, one outcome, which necessarily was not even related to the stem cell infusion, is attracting so much attention, WHILE ON THE OTHER HAND NO ONE DISCUSSES THE FACT THAT EMBRYONIC STEM CELLS CAUSE CANCERS CALLED TERATOMAS!!!

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS - IH).

The paper identified two barriers: a wide variation in EGFRvIII expression in patients and a resistance in the tumor microenvironment, which researchers showed became even more immunosuppressive following CAR T cell infusion.

Not exact matches

The drug was a single infusion of a patient's own immune cells that have been modified reprogramed to attack their deadly cancer.

The news is particularly relevant in light of the fact that many common health issues with newborns are linked to developmental problems with their organs, a situation that might be aided by the infusion of stem cells, which can mature into any organ in the body.

(Patients may also receive infusions of white cells that help fight infection or platelets, the small, colorless cell fragments that help stanch bleeding by clotting.)

«Transplanted hematopoietic stem cells reverse damage caused by neuro - muscular disorder: In mouse model of Friedreich's ataxia, a single infusion measurably restored normal cellular functions.»

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.

In an ongoing trial of umbilical cord infusions» effects on autism symptoms, Kurtzberg and her colleagues are comparing the effects of children's own cells and donor cells.

Future studies may involve infusion of higher numbers of altered cells.

In that case, six patients suspended antiretroviral therapy for 12 weeks after infusion with zinc finger nuclease — altered CD4 cells.

Patients in the trial had been on ibrutinib for a minimum of six months and had not achieved a complete response when they received an infusion of engineered cells split over three consecutive days.

The patients received biweekly infusions of nivolumab, which is an antibody that blocks a protein called PD - 1 on the surface of immune system T cells.

«Infusions of mesenchymal stem cells are not transplants in any way.

All 10 patients who received the CTL119 cells experienced mild cytokine release syndrome (CRS), a known potentially lethal type of toxicity, within a few days after receiving their infusions; however, none required treatment with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL - 6.

They also gave old mice infusions of young blood plasma (the liquid component of blood containing proteins and hormones but no cells), which significantly improved their performance in learning and memory tests.

Then there's the West Palm Beach symposium, held to recruit participants for a study testing what happens when aging people get infusions of plasma (the fluid part of blood packed with signaling proteins and other molecules but no red or white cells) from young people who've taken a drug meant to activate their immune system.

One drawback is that patients will have to come into a clinic for vitamin C infusions, ideally every few days for months, because vitamin C seems to take that long to kill cancer cells, Levine notes.

He is pioneering a new treatment for autoimmune disorders, one in which patients» immune systems are suppressed and then replaced with an infusion of their own immune stem cells, filtered out from their blood.

In the phase I / II clinical trial of 20 patients, the engineered cells were deemed safe, trafficked to the site of the tumor (bone marrow), and persisted in 90 percent of the patients who reached two years follow up after infusion, the research team found.

The next step is to increase the percentage of genetically engineered cells, either by increasing the amount of cells in the infusion, by giving more than one infusion, or by administering chemotherapy to lower the number of untreated CD4 cells in the body before infusion begins.

All the infused patients also had detectable circulating CART - EGFRvIII cells in the blood in the first month after infusion.

«There is a dramatic expansion of inhibitory T cells in the tumors after the infusion, much more significant than what you see without the CAR T cells,» O'Rourke said.

In September 2010 Sharp received a single infusion of 20 billion of his genetically engineered immune cells.

Within the first two weeks of infusion, a detectable number of CART - EGFRvIII cells trafficked to the tumors, with signs of activation in the four patients who had «early surgery,» the researchers reported.

Here, six patients suspended combination antiretroviral therapy for 12 weeks after infusion with altered CD4 cells, so scientists could monitor viral load and the power of the altered immune cells to survive and thrive in the presence of active HIV.

All patients who received the CTL019 «hunter» cells experienced a cytokine release syndrome (CRS) within a few days after receiving their infusions — a key indicator that the engineered cells have begun proliferating and killing tumor cells in the body.

Given to the patient shortly before the transplant, the infusion of antibodies theoretically reduces the host's residual T cells, minimizing the risk of graft rejection while eliminating T cells from the donor to thwart GVHD.

The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.

The researchers say the results suggest that both the dose of T cells administered and the infusion regimen (one large dose vs several smaller doses) are important to maximize both response and safety.

The next six patients received the same cell dose as a one - time infusion.

The research team then treated 9 patients with a lower cell dose (5 x 107 cells), as either a one - time or a split - dose infusion.

VRC01 infusion did not affect the quantity of HIV in blood cells in any of the 23 study patients.

Several early stage clinical trials using autologous infusions of ZFN - generated CCR5 - modified CD4 + T cells are currently underway (clinicaltrials.gov identifiers NCT00842634, NCT01252641, NCT01044654).

Infusion of haploidentical natural killer (NK) cells: Patients with relapsed neuroblastoma (NCT00698009)

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

At Okyanos, adult stem cells are derived from a patient's own body fat and delivered directly to the heart via an infusion into the coronary sinus.

They found out that pre-organ transplant infusion of MSC in 1 or 2 doses [on day - 7 and day - 1] induced a profound T cell hyporesponsiveness and prolonged B6C3 cardiac allograft survival.

For the other adult patients that might still benefit from a cord blood donor, either two cord blood units are combined for a single transplant, or more recently, there are some exciting new graft engineering technologies that are emerging to expand stem or progenitor cells in the laboratory before infusion or modify the cells in some way to make them more potent at the time of transplant.

To determine the role of inflammatory response in the pathophysiology of these diseases, glial cell morphology and essential functions, such as glutamate transport, ion recapture and modulation of neurotransmission will be evaluated following infusion of autoantibodies in the hippocampus.

In an outpatient blood and bone marrow stem cell transplant, the patient undergoes the full course of treatment (pre-transplant evaluation, conditioning, infusion of their stem cells, engraftment and recovery) on an outpatient basis rather than being admitted to the hospital for three to four weeks of treatment.

This involves the infusion of the freshly collected donated cells into your bloodstream.

A team of researchers from the University of Iowa and Veterans Affairs Research Communications, led by Dr. Markus Kuehn, has found that an infusion of stem cells could help treat eyes at risk for glaucoma by restoring proper drainage in fluid - clogged eyes.

After infusion, the signal from the genetically modified T cells in the peripheral blood increased up to 100-fold and the DNRII - LSTs persisted for up to 4 years, according to the authors.

Regenerative cells are then delivered directly into all fingers of both hands, as well as systemically by intravenous infusion.

This treatment delivers an infusion of adult stem cells safely to the heart to address pumping function for symptomatic relief and a better quality of life.

The infusion of ex vivo activated and expanded CD4 (+) CD25 (+) immune regulatory cells inhibits graft - versus - host disease lethality.